Mylan sued in US court over generic Caduet ANDA
This article was originally published in Scrip
Executive Summary
Pfizer has filed suit in a US district court in Delaware against Mylan, alleging patent infringement related to its generic version of the single pill Caduet, a combination of lipid-lowering Lipitor (atorvastatin) and the antihypertensive Norvasc (amlodipine besylate). Pfizer seeks to protect its franchise, and alleges infringement of US patent No 6,455,574, which is set to expire in August 2018.